The latest addition to The Woodlands’ life sciences core is open for business, and it could attract more businesses to the ...

RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that Andres Isaias, its Chief ...

The 12-year-old biotech had been collaborating with British pharmaceutical giant GlaxoSmithKline on an immuno-oncology drug ...

In all, 24 lawyers and 20 professional staff from Boston-founded boutique Faber Daeufer & Itrato will be joining Crowell in ...

The panelists laid out some reasons for optimism about the future of innovation in our state, and also some reasons for ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Healthpeak’s development projects across its life science portfolio should be completed at development yields above the company's weighted average cost of capital and could drive strong internal ...

China is now setting the pace in life sciences R&D, conducting more clinical trials than the U.S. and licensing new ...

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...